Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

Abstract

Background:

The immunogenicity of influenza vaccines in MS patients undergoing immunomodulatory treatment is not well studied.

Objectives:

This explorative study investigated the influence of immunomodulatory treatment on MS patients receiving pandemic H1N1 (swine flu) vaccination in 2009 and seasonal influenza vaccination in 2010.

Methods:

We investigated the immune response to pandemic H1N1 vaccination among 113 MS patients and 216 controls during the pandemic of 2009. We also investigated the serological response to seasonal influenza vaccination (2010 – 2011 season) among 49 vaccinated and 62 non-vaccinated MS patients, versus 73 controls. We evaluated these vaccine responses by haemagglutination inhibition assay.

Results:

MS patients receiving immunomodulatory treatment had reduced protection (27.4%), compared to controls (43.5%) (p = 0.006), after pandemic H1N1 vaccination (2009). The rates of protection were not influenced by interferon beta treatment (44.4% protected), but were reduced among patients receiving glatiramer acetate (21.6%), natalizumab (23.5%), and mitoxantrone (0.0%). A similar pattern emerged after MS patients received a seasonal influenza vaccination in 2010.

Conclusions:

These findings suggest that MS patients receiving immunomodulatory therapies other than interferon beta should be considered for a vaccine response analysis and perhaps be offered a second dose of the vaccine, in cases of insufficient protection.

Keywords

Immunity immunomodulation immunotherapy influenza multiple sclerosis pandemic influenza protection risk vaccination

Get full access to this article

View all access options for this article.

References

Oikonen

Laaksonen

Aalto

. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler 2011; 17: 672–680.

Miller

Morgante

Buchwald

. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997; 48: 312–314.

Confavreux

Suissa

Saddier

. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001; 344: 319–326.

Auriel

Gadoth

Regev

. Seasonal and H1N1v influenza vaccines in MS: Safety and compliance. J Neurol Sci 2012; 314: 102–103.

Rutschmann

McCrory

Matchar

. Immunization and MS: A summary of published evidence and recommendations. Neurology 2002; 59: 1837–1843.

Schwid

Decker

Lopez-Bresnahan

. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology 2005; 65: 1964–1966.

Vagberg

Kumlin

Svenningsson

. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res 2012; 34: 730–733.

Mehling

Hilbert

Fritz

. Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 2011; 69: 408–413.

Kappos

Arroyo

Izquierdoet

. A controlled study on the effect of fingolimod (FTY720) on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with multiple sclerosis. Mult Scler J 2011; 17: 126.

10.

Kappos

. Effect of fingolimod on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with MS. Paper presented at Ectrims, Amsterdam, The Netherlands, 20 October 2011.

11.

Pathirana

Bredholt

Akselsen

. A(H1N1)pdm09 vaccination of health care workers: Improved immune responses in low responders following revaccination. J Infect Dis 2012; 206: 1660–1669.

12.

Pebody

Andrews

Fleming

. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect 2012; 1–11.

13.

Walker

De Whalley

Andrews

. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: A multicenter follow-on study. Clin Infect Dis 2012; 54: 661–669.

14.

Bar-Or

Freedman

Kremenchutzky

. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology 2013; 81: 552–558.

15.

Moriabadi

Niewiesk

Kruse

. Influenza vaccination in MS: Absence of T-cell response against white matter proteins. Neurology 2001; 56: 938–943.

16.

McNicholas

Chataway

. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol 2011; 258: 1545–1547.

17.

De Keyser

Zwanikken

Boon

. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998; 159: 51–53.